• by Bruce Carlson
  • November 15 2017


Oncology Remains Most Active, Highest-Growth Area for LDTs

Oncology Remains Most Active, Highest-Growth Area for LDTs

There will be a robust market for LDTs because there aren't enough commercial test solutions for the clinical needs of labs. So predicts a report from Kalorama.


Letting Robots Do the Menial Work So Labs Don't Have To

Reducing the time wasted taking on preparation and maintenance steps will give clinicians and technicians more time to devote to the more important task of analyzing the results, getting more actual research done, and moving on to the next big study sooner. In this article, based on Kalorama's Robotic Laboratory Automation report, we discuss these steps.

  • by Bruce Carlson
  • October 24 2017


Four Trends in Clinical Chemistry

Four Trends in Clinical Chemistry

Watch these 4 important trends with in the largest and most basic category of IVD testing, from Kalorama Information's complete study of the market.


Five Reasons to Be Bullish on Medical Devices

Five Reasons to Be Bullish on Medical Devices

Kalorama Information has increased our projection of the growth rate for the overall medical device market. From pharmaceutical replacement to advanced pricing, This article summarizes the reasons why, though it's not all upside, and there is greater explanation and data in our 2017 global medical device report.

  • by Aaron Hackle
  • October 6 2017


CMS's Deep PAMA Cuts Surprise Industry

CMS's Deep PAMA Cuts Surprise Industry

PAMA's price cuts were even higher than Kalorama had predicted in June, but some advanced testmakers got good news.

  • by Bruce Carlson
  • September 29 2017


Kalorama’s Knowledge Center Now Available to Government Agencies via Carahsoft

Kalorama’s Knowledge Center Now Available to Government Agencies via Carahsoft

Although Kalorama Information reports find use among executives engaging in business planning or considering competitive actions or product launches, they can also be useful for government agencies.

  • by Bruce Carlson
  • September 26 2017


Malignant Mesothelioma: Another Job for Liquid Biopsy

Malignant Mesothelioma: Another Job for Liquid Biopsy

Mesothelioma treatment is imperiled by late detection. New non-invasive liquid biopsy approaches are showing promise, as this article demonstrates.


Five Factors Boosting Immunoassays

Five Factors Boosting Immunoassays

From metabolic disease to infections to cancer, these tests are the standbys for the laboratory. And according to a new Kalorama they are here to stay.


IVD Can Contribute to t-mAb Effectiveness

Therapeutic monoclonal antibodies are useful therapies but in some cases they work for a period, then lose their effectiveness The role of testing in preventing therapeutic monoclonal antibodies from failing has recently received high-profile attention, with a session at AACC and in other places This blog piece by Kalorama analyst Rob Camp, PhD, looks at the role of testing.


Molecular POC Makes Strides

Molecular POC Makes Strides

Six companies to watch in the development of rapid and small footprint DNA testing near patient.